OVA (257-264) Chicken Ovalbumin Peptide - SIINFEKL

About OVA (257-264) Chicken Ovalbumin Peptide - SIINFEKL

OVA 257-264 (SIINFEKL) is a well-characterized, immunodominant epitope derived from chicken ovalbumin protein (Uniprot P01012). This specific sequence, SIINFEKL, is frequently used in immunological assays due to its strong binding affinity to the H-2Kb molecule in MHC class I. Unlike complexes or dextramers, JPT's OVA antigen peptide is provided as a standalone peptide, which allows for broad applications in T cell assays such as ELISPOT, ICS, and cytotoxicity testing. Researchers often leverage OVA 257-264 in antibody production, epitope mapping, and the stimulation of antigen-specific CD8+ T cells to observe immune responses.

The Chicken Ovalbumin Peptide is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Ovalbumin Peptide, H-SIINFEKL-OH (Uniprot: P01012 aa: 257-264) from JPT is produced under strict quality control and quality management. CAS: 138831-86-4

OVA (257-264) Chicken Ovalbumin Peptide - SIINFEKL - Specifications

• Peptide sequence: H-SIINFEKL-OH
• Amount: 1 mg
• Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
• Delivery Format: Freeze-dried in plastic vial
• CAS: 138831-86-4
• Application(s): T-cell immunity
• Condition(s)/Topic(s): Control, Infectious mononucleosis, Opportunistic infections
• Standard Delivery Time: approx. 10 days

Applications of OVA 257-264 (SIINFEKL) Antigen Peptide

• Stimulation of Antigen-Specific T Cells: Commonly used in assays to evaluate T cell functionality, the SIINFEKL epitope allows scientists to monitor CD8+ cytolytic responses with precision.
• Loading of Tetramers/Dextramers: Our peptide serves as an ideal component for T cell receptor (TCR) binding studies and the formation of multimer complexes for more advanced immune monitoring.
• Development of Immune Assays: By using SIINFEKL, scientists can perform ICS, ELISPOT, cytotoxicity, and proliferation assays with confidence.
• Antibody Production and Vaccine Development: Due to its strong immune response induction, the SIINFEKL peptide is valuable in preclinical studies focused on immunotherapy, vaccine trials, and epitope-based diagnostics.

Your Custom or Scrambled Antigen Peptide!

Do you need a scrambled version of this antigen peptide?
We can produce scrambled versions for all our antigen peptides and other peptide sequences. These scrambled peptide versions are cross-checked against the Uniprot database to ensure that the scrambled sequence does not correspond to any natural sequence. Have a look at Scrambled Antigen Peptides!

Are you interested in other antigen peptides?
Choose sequence, amount and purity. We will assist you along the way: Custom Peptide Synthesis

JPT's Premium Antigen Peptides

At JPT Peptide Technologies, we offer a broad selection of antigen peptides like OVA (257-264), accompanied by PepMix™ Peptide Pools and MHC Multimers tailored for effective immune monitoring and therapeutic development. As a trusted partner in peptide synthesis, JPT is known for its precision-driven approach, ensuring peptides are synthesized with high purity and rigorously analyzed by HPLC-MS to validate identity and quality.

Advantages of Choosing JPT's Antigen Peptides

• Manufactured in Germany: All peptides, including OVA (257-264) with the sequence SIINFEKL, are produced under restricted regulations in Germany, ensuring the highest quality standards.
• Custom and Bulk Synthesis Options: We provide custom peptide synthesis upon request and offer bulk orders to accommodate high-throughput research needs.
• Purity and Safety: With synthesis protocols designed to prevent toxic contaminants and side products, our peptides maintain high safety and purity.
• Stability and Storage: Our peptides are delivered as freeze-dried aliquots, enhancing stability and making them suitable for long-term storage.
• Proven Performance: JPT's antigen peptides, have demonstrated efficacy in numerous clinical and preclinical studies.